Journal article
The prevalence, age distribution and comorbidity of personality disorders in Australian women
Shae E Quirk, Michael Berk, Julie A Pasco, Sharon L Brennan-Olsen, Andrew M Chanen, Heli Koivumaa-Honkanen, Lisa M Burke, Henry J Jackson, Carol Hulbert, Craig A Olsson, Paul Moran, Amanda L Stuart, Lana J Williams
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | SAGE PUBLICATIONS LTD | Published : 2017
Abstract
OBJECTIVE: We aimed to describe the prevalence and age distribution of personality disorders and their comorbidity with other psychiatric disorders in an age-stratified sample of Australian women aged ⩾25 years. METHODS: Individual personality disorders (paranoid, schizoid, schizotypal, histrionic, narcissistic, borderline, antisocial, avoidant, dependent, obsessive-compulsive), lifetime mood, anxiety, eating and substance misuse disorders were diagnosed utilising validated semi-structured clinical interviews (Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition and Structured Clinical Interview for DSM-IV Axis II Personality Disorders). The pre..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC of Australia)
Awarded by NHMRC Public Health and Health Services Research Postgraduate Scholarship
Awarded by NHMRC Senior Principal Research Fellowship
Awarded by NHMRC Career Development Fellowship
Awarded by ARC Senior Research Fellowship
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Geelong Osteoporosis Study is funded by the National Health and Medical Research Council (NHMRC of Australia, projects 454356 and 628582) and the Victorian Health Promotion Foundation. S.E.Q. was supported by a NHMRC Public Health and Health Services Research Postgraduate Scholarship (GNT1076347) and is currently supported by a Deakin University Health Research Postdoctoral Fellowship. M.B. has received Grant/Research Support from the National Institute of Health (USA), Simons Foundation, CRC for Mental Health, Stanley Medical Research Institute, Medical Benefits Fund, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Pfizer; a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth; and is supported by a NHMRC Senior Principal Research Fellowship (GNT1059660). J.A.P. has received grants from the NHMRC, BUPA Foundation, Deakin University, Barwon Health and the Western Alliance Academic Health Science Centre. S.L.B.-O. has received Grant/Research support from The University of Melbourne, Deakin University, an Alfred Deakin Postdoctoral Research Fellowship, has received speaker fees from Amgen (2015) and is currently supported by a NHMRC Career Development Fellowship (GNT1107510). A.M.C. has received research funding from the NHMRC, Australian Research Council (ARC), Colonial Foundation, The University of Melbourne, Melbourne Health and the New South Wales Department of Health. H.J.J. has received funding from NHMRC, ARC, University of Melbourne, Beyond Blue and Australian Rotary Health. C.A.O. was supported by an ARC Senior Research Fellowship (DORA: DP130101459). L.J.W. has received Grant/Research support from Eli Lilly, Pfizer, The University of Melbourne, Deakin University and the NHMRC, and is supported by a NHMRC Career Development Fellowship (GNT1064272).